Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 4/20 | 0.58 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.58 |
| ▸ | CDK4 | P11802 | 7/20 | 0.52 |
| ▸ | CCND1 | P24385 | 7/20 | 0.52 |
| ▸ | CCND2 | P30279 | 3/20 | 0.52 |
| ▸ | CCND3 | P30281 | 3/20 | 0.52 |
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | CDK2 | P24941 | 3/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.51 |
| ▸ | WEE1 | P30291 | 3/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.50 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.50 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.50 |
| ▸ | STK17B | O94768 | 1/20 | 0.48 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5501445 | 0.89 | MAP4K1 (0.64) | STK17ACDK4CCND1CCND3BRD4 | |
| SCHEMBL229526 | 0.85 | ALK (0.59) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL230101 | 0.81 | BRAF (0.50) | MAP4K1 | |
| SCHEMBL2573809 | 0.80 | YES1 (0.53) | PDGFRBPDGFRAFGFR1FGFR4 | |
| SCHEMBL2573807 | 0.80 | SRC (0.53) | WEE1FGFR1FGFR4 | |
| SCHEMBL4892563 | 0.78 | CCND3 (0.56) | STK17AMYLK4CDK4CCND1CCND2 | |
| SCHEMBL230249 | 0.75 | SRC (0.77) | PDGFRBFGFR1FGFR2 | |
| SCHEMBL231133 | 0.74 | SRC (0.51) | PDGFRBFGFR1 | |
| SCHEMBL14195191 | 0.74 | HTR1A (0.51) | STK17AMYLK4CDK4CCND1CCND2 | |
| SCHEMBL5494435 | 0.74 | MAP4K1 (0.57) | STK17ACDK4CCND1BRD4MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | claimed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | claimed |
| EP-2381943-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | Fovea Pharmaceuticals (FR) | 2011-11-02 | — | — | EP | claimed |
| WO-2010076238-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA (FR) | 2010-07-08 | — | — | WO | claimed |
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | disclosed |
| EP-2381943-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | Fovea Pharmaceuticals (FR) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010076238-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA (FR) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | MAP3K5, MAP3K1, MAP3K2 | STK17A 248/4885MYLK4 286/4885CDK4 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.